FOLH1 and pachyonychia congenita: In addition, these studies utilized PSMA PET imaging with [68Ga]Ga-PSMA-11, which is currently the only radiopharmaceutical approved by the FDA for assessing PSMA-positive PC lesions (88), although current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and American Society of Clinical Oncology guidelines state that all FDA-approved radioligand tracers (namely [68Ga]Ga-PSMA-11, [18F]DCFPyL, and [18F]rhPSMA-7.3) can be used for identifying suitable patients (71, 89).